The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.

about

Dapagliflozin for the treatment of type 1 diabetes mellitus.Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016).Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?

P2860

Q39354776-32CA92F3-4158-4CA1-A47E-6D530323D32E Q39382164-67561E49-9CD7-445E-B2CF-0FDA54E17A53 Q48263840-3E41848F-9DDC-43AC-820A-50A4BE595802

P2860

The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.

Item

http://www.wikidata.org/entity/Q38908779

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

The potential of SGLT2 inhibit ...... for treating type 2 diabetes.

@en

type

Item

label

The potential of SGLT2 inhibit ...... for treating type 2 diabetes.

@en

prefLabel

The potential of SGLT2 inhibit ...... for treating type 2 diabetes.

@en

P1476

The potential of SGLT2 inhibit ...... for treating type 2 diabetes.

@en

P2093

K Pafili

http://www.w3.org/2001/XMLSchema#string

N Papanas

http://www.w3.org/2001/XMLSchema#string

P2860

SGLT2 Inhibitors May Predispose to Ketoacidosis

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

P304

1133-1152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2016.1216970

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Efstratios Maltezos

P577

2016-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27459025

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.

about

P2860

P2860

The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921